EDAP TMS SA ADR(FOCL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.04 | Insider Own | 0.53% | Shs Outstand | 37.5M | Perf Week | 0.24% |
| Market Cap | 0.16B | Forward P/E | - | EPS next Y | 24.06% | Insider Trans | 173.45% | Shs Float | 37.3M | Perf Month | -3.24% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.24 | Inst Own | 49.74% | Short Float | 0.9% | Perf Quarter | -29.98% |
| Income | -0.04B | P/S | 2.27 | EPS this Y | -33.08% | Inst Trans | 1.01% | Short Ratio | 3.06 | Perf Half Y | 20.46% |
| Sales | 0.07B | P/B | - | EPS next 5Y | 7.02% | ROA | -50.16% | Short Interest | 0.33M | Perf YTD | 27.05% |
| Book/sh | -0.09 | P/C | 7.27 | EPS past 3/5Y | -106.02% -63.72% | ROE | -263.75% | 52W High | -34.69% ($6.40) | Perf Year | 92.63% |
| Cash/sh | 0.57 | P/FCF | - | Sales past 3/5Y | 6.9% 8.3% | ROIC | -111.73% | 52W Low | 129.67% ($1.82) | Perf 3Y | -34.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -81.03% | Gross Margin | 48.73% | Volatility(W/M) | 6.36% 6.16% | Perf 5Y | -31.25% |
| Dividend TTM | - | EV/Sales | 2.56 | Sales Y/Y TTM | - | Oper. Margin | -39.32% | ATR (14) | 0.26 | Perf 10Y | 54.24% |
| Dividend Ex-Date | - | Quick Ratio | 1.38 | EPS Q/Q | -127.3% | Profit Margin | -56.25% | RSI (14) | 47.6 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.6 | Sales Q/Q | -27.49% | SMA20 | -0.04% ($4.18) | Beta | -0.02 | Target Price | $8.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/5 | SMA50 | -1.64% ($4.25) | Rel Volume | 0.6 | Prev Close | $4.17 |
| Employees | 289 | LT Debt/Eq | - | EPS/Sales Surpr. | -81.23% -12.49% | SMA200 | -5.18% ($4.41) | Avg Volume(3M) | 0.11M | Price | $4.18 |
| IPO | 1997/8/1 | Option/Short | Yes/Yes | Trades | 131 | Volume | 66,143 | Change | 0.24% |
🩺 A healthcare company developing robotic-based local therapy medical devices. Its core offering is a non-invasive treatment platform that combines focused ultrasound technology with imaging, treatment planning, and robotic precision control, with a focus on treating localized lesions such as those in the prostate. It is a specialized medical device company headquartered in France that supplies medical devices to the global market.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded less than usual. That is 60% of its average volume.
Next earnings report: November 5
4 days to go.
FOCL has a sound balance sheet but weak earning power
Of every $100 in sales, $39.32 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -33.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $227. Peers typically go for $285.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -31.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 49.7%.
Tap to view numbers
It ranks #6 of 10 in the industry
Based on market cap of $157M.
AHG#5 Akso Health Group ADR $1B PER - FOCL#6 EDAP TMS SA ADR $157M PER - 
COSM#7 Cosmos Health Inc $31M PER - 
ACH#8 Accendra Health Inc $20M PER - 
YI#9 111 Inc ADR $15M PER - 
FAQ
What kind of company is FOCL?
FOCL belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is the market cap of FOCL?
The market cap of FOCL is approximately $157M, ranking 4,190 within its sector.
What is the 52-week high and low for FOCL?
FOCL has recorded a 52-week high of $6.40 and a low of $1.82.
